The study emphasizes real dupilumab experiences for people with COPD

In a case series that was recently presented at the American Thoracic Society (ATS) 2025 International Conference in San Francisco, it was shown that dupilumab (dupixent) is safe and generally well tolerated in patients with chronic obstructive lung disease (COPD) and increased eosinophil numbers.¹

The data that indicates that the use of dupilumab is related to fewer exacerbations and improvements in the patient's COPD symptoms, as proposed by patients with patients reported results. This analysis, which was presented in a poster meeting at ATS, was written with the title “Real-World Experience of Dupilumab treatment for patients with COPD” and by researchers such as Ophir Freund, MD, from Tel Aviv Sourasky Medical Center.¹

Before this examination, a dupilumab was found that in people with COPD, which are marked by inflammation of type 2, effectiveness had recently demonstrated. However, friend and colleagues found that the routine clinical practice data were scarce before this analysis, and therefore their study was carried out to examine the real results in COPD with dupilumab treatment.

People with COPD who were treated one after the other were invited to participate in this analysis, whereby a structured interview was first utched by the investigation team. The criteria for the authorization in the study included a basic blood -eosinophil number of ≥ 300 cells/μl. In addition, those who are considered for the authorization would have to have at least one tightening of their COPD, which, despite the continued therapy therapy therapy use, was found in the previous year.

There were a total of 14 people who were rated by friends and co -authors throughout the analysis. These subjects reported [IQR] 173–195). The severity of their illness based on gold classification was gold 3E in 43% and gold 4E in 21% of the people involved in the study.

Overall, the investigation team came to the conclusion that the median number of COPD examinations of the participants showed a reduction from 2 (IQR 2–2) to 1 (IQR 0–1) to 1 (IQR 0–1) during the treatment of the DuPilumab. In addition, the team emphasized a decline in the Median COPD evaluation tests of the study persons (CAT) from 17 to 14, which they found that they would indicate a symptomatic improvement.

The lack of changes was also made by Freund et al. Found in a single second (FEV₁). In addition, the investigators stated that a single experimenter reported on a dermatological undesirable event.

Friends and colleagues found that the results registered in the study were generally positive in the study participants. 69% of the participants emphasize their own satisfaction with the use of Dupilumab. They also pointed out to signs of 62% of those in the study that they would recommend the drug to other people who live with COPD.

After the global evaluation of the treatment effectiveness (GETE), 38% of the participants gave about a higher clinical improvement. The team found that the most frequently cited treatment barriers under 50%and the most common injection requirements were classified as costs in 29%. The interest of the interest in new and safe therapeutic alternatives was further referred to among those involved in this analysis.

Overall, the researchers' case series would indicate that DuPilumab can be regarded as a safe and generally well -tolerated treatment for COPD in patients who indicate that the number of eosinophils is increased. The use of this therapeutic option was associated with fewer illnesses and improvements in symptoms, as reported by patients with patients.

Further information on new data presented at ATS can be found in the latest reporting on the conference.

References

1. Freund O, Meoded O, Bar-Shai a et al. (Poster Board # P899) Real experience with dupilumab treatment in patients with COPD. Abstract presented by the International Conference 2025 of the American Thoracic Society (ATS) in San Francisco, CA, from May 18, 2025.